Samuel Ray Denmeade MD

Oncology•Baltimore, MD

Professor of Oncology, Professor of Urology, Johns Hopkins University School of Medicine

Join to View Full Profile

201 North Broadway StreetViragh BLDG 5th FLBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194

Summary

Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Director of the Genitourinary Oncology Program at Johns Hopkins in Baltimore, MD. He is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 28 years. He is experienced in treatment of advanced prostate cancer. He has more than 200 publications and developed the concept of Bipolar Androgen Therapy for metastatic prostate cancer

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1996
University of ChicagoResidency, Internal Medicine, 1989 - 1992
Columbia University Vagelos College of Physicians and SurgeonsClass of 1989

Certifications & Licensure

MD State Medical License 1993 - 2026
PA State Medical License 1992 - 2026
VA State Medical License 2024 - 2026
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012

Clinical Trials

A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer Start of enrollment: 2010 Mar 01
Completed
Not Applicable
Bipolar Androgen-based Therapy for Prostate Cancer (BAT) Start of enrollment: 2013 Jan 01
Completed
Phase 2
Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer Start of enrollment: 2013 Oct 01
Terminated
Phase 1
RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) Start of enrollment: 2014 Aug 25
Completed
Phase 2
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Start of enrollment: 2015 Mar 28
Active, not recruiting
Phase 2
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2017 Feb 09
Terminated
Phase 1
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Start of enrollment: 2020 Aug 19
RECRUITING
PHASE2
Trial to Promote Recovery From COVID-19 With Endocrine Therapy Start of enrollment: 2021 Apr 01
Withdrawn
Phase 2
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer Start of enrollment: 2022 Mar 07
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Rando...
Jarey H Wang, Alexander D Sherry, Soha Bazyar, Philip Sutera, Noura Radwan
Journal of Clinical Oncology. 2025-06-20
4 citations
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
David R Wise, Russell K Pachynski, Samuel R Denmeade, Rahul R Aggarwal, Jiehui Deng
Prostate Cancer and Prostatic Diseases. 2025-06-01
Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.
Mayuko Kanayama, Hua-Ling Tsai, Hao Wang, Emmanuel S Antonarakis, Samuel R Denmeade
Prostate Cancer and Prostatic Diseases. 2025-06-01

Journal Articles

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
Emmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology

Press Mentions

Prostate Cancer Drug Is Found to Be an Effective Antiviral Against Coronavirus and the Common ColdFebruary 3rd, 2021
Health Tips: This Experimental Prostate Cancer Treatment Is Shrinking TumorsApril 29th, 2017
Health Tips This Experimental Prostate Cancer Treatment Is Shrinking TumorsApril 28th, 2017
Join now to see all

Grant Support

SPORE in Prostate CancerJOHNS HOPKINS UNIVERSITY2024–2029
SPORE in Prostate CancerJOHNS HOPKINS UNIVERSITY2024–2029
SPORE in Prostate CancerJOHNS HOPKINS UNIVERSITY2024–2029
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune ResponseJOHNS HOPKINS UNIVERSITY2021–2027
The Role of Myeloid-Derived Suppressor Cells in Resistance to Bipolar Androgen Therapy in Patients with Advanced Prostate CancerJOHNS HOPKINS UNIVERSITY2023–2025

Other Languages

Spanish

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/samuel-denmeade